SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity

Acta Pharmacologica Sinica

Volumn 34, Issue 9, 2013, Pages 1149-1155

  Fang, Xing ^a   Guo, Lin ^a   Jia, Jia ^b   Jin, Guo Zhang ^a   Zhao, Bin ^c   Zheng, Yong Yong ^d   Li, Jian Qi ^d   Zhang, Ao ^a   Zhen, Xue Chu ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SOOCHOW UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

Author keywords

Depression; Dopamine; DOV21947; Monoamine transporter; Norepinephrine; Serotonin; SKF83959

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; AMITIFADINE; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TRIPLE REUPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIDEPRESSIVE AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DEPRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, INBRED C57BL; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84883658976     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.66     Document Type: Article

References (36)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
2. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 2009; 11: 239-55.
3. Millan MJ. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 2004; 500: 371-84.
4. Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009; 18: 767-88.
5. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003; 73: 3175-9.
6. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003; 461: 99-104.
7. Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, et al. The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 2008; 18: 908-16.
8. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 2008; 327: 573-83.
9. Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 2008; 587: 141-6.
10. Andringa G, Drukarch B, Leysen JE, Cools AR, Stoof JC. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 1999; 364: 33-41.
11. Makihara Y, Okuda Y, Kawada C, Matsumoto M, Waddington JL, Koshikawa N, et al. Differential involvement of cyclase-versus non-cyclase-coupled D1-like dopamine receptors in orofacial movement topography in mice: studies with SKF 83822. Neurosci Lett 2007; 415: 6-10.
12. Rashid AJ, O'Dowd BF, Verma V, George SR. Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends Pharmacol Sci 2007; 28: 551-5.
13. Fujita S, Kiguchi M, Kobayashi M, Kinsella A, Koshikawa N, Waddington JL. Assessment of jaw movements by magnetic sensor in relation to topographies of orofacial behaviour in freely moving rats: Studies with the dopamine D1-like receptor agonists SKF 83822 vs SKF 83959. Eur J Pharmacol 2010; 632: 39-44.
14. Panchalingam S, Undie AS. SKF83959 exhibits biochemical agonism by stimulating [35S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 2001; 40: 826-37.
15. Cools AR, Lubbers L, van Oosten RV, Andringa G. SKF83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacology 2002; 42: 237-45.
16. Jin LQ, Goswami S, Cai G, Zhen X, Friedman E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 2003; 85: 378-86.
17. O'Sullivan GJ, Clifford JJ, Tomiyama K, Koshikawa N, Drago J, Sibley DR, et al. D1-like dopamine receptor-mediated function in congenic mutants with D1 vs D5 receptor "knockout". J Recept Signal Transduct Res 2004; 24: 107-16.
18. Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undieh AS. D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol 2009; 75: 447-53.
19. Ming Y, Zhang H, Long L, Wang F, Chen J, Zhen X. Modulation of Ca2+ signals by phosphatidylinositol-linked novel D1 dopamine receptor in hippocampal neurons. J Neurochem 2006; 98: 1316-23.
20. Undieh AS. Pharmacology of signaling induced by dopamine D1-like receptor activation. Pharmacol Ther 2010; 128: 37-60.
21. Andringa G, Stoof JC, Cools AR. Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) 1999; 146: 328-34.
22. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease - the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology (Berl) 1995; 117: 403-12.
23. Zhang H, Ma L, Wang F, Chen J, Zhen X. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 2007; 53: 125-33.
24. Zhen X, Goswami S, Friedman E. The role of the phosphatidylinositol- linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 2005; 80: 597-601.
25. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, Jin GZ, et al. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action. J Neurochem 2008; 104: 946-56.
26. Chu HY, Wu Q, Zhou S, Cao X, Zhang A, Jin GZ, et al. SKF83959 suppresses excitatory synaptic transmission in rat hippocampus via a dopamine receptor-independent mechanism. J Neurosci Res 2011; 89: 1259-66.
27. Chen XQ, Zhang J, Neumeyer JL, Jin GZ, Hu GY, Zhang A, et al. Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effects. PLoS One 2009; 4: e5811.
28. Chu HY, Yang Z, Zhao B, Jin GZ, Hu GY, Zhen X. Activation of phosphatidylinositol-linked D1-like receptors increases spontaneous glutamate release in rat somatosensory cortical neurons in vitro. Brain Res 2010; 1343: 20-7.
29. Zheng YY, Guo L, Zhen XC, Li JQ. Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors. Eur J Med Chem 2012; 54: 123-36.
30. Zhao G, Li S, Qin GW, Fei J, Guo LH. Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter. J Ethnopharmacol 2007; 112: 498-506.
31. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-2.
32. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985; 85: 367-70.
33. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000; 5: 357-62.
34. Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 2007; 16: 1365-77.
35. Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amiti-fadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012; 46: 64-71.
36. Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009; 10: 1069-84.